{
  "timestamp": "2026-01-20T01:44:19.066072",
  "method": "llm",
  "judge_model": "claude-3-haiku-20240307",
  "source_file": "/Users/shloknatarajan/stanford/research/daneshjou/autogkb-benchmark/src/experiments/sentence_generation/batch_judge_ask/outputs/gpt-4o-mini_v5_20260120_014412.json",
  "overall_avg_score": 0.837,
  "num_pmcids": 1,
  "per_pmcid": [
    {
      "pmcid": "PMC5508045",
      "avg_score": 0.837,
      "num_variants": 4,
      "per_variant": [
        {
          "variant": "rs9923231",
          "ground_truth": [
            "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC."
          ],
          "generated": [
            "Genotypes AA + AG of rs9923231 are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to genotype GG.  \nEXPLANATION: The study found that the AA and AG genotypes were linked to lower warfarin dose requirements, contributing significantly to the variability in stable warfarin doses among the 250 Thai patients (p < 0.01)."
          ],
          "score": 0.85,
          "best_similarity": 0.3492063492063492,
          "best_gt": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
          "best_gen": "Genotypes AA + AG of rs9923231 are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to genotype GG.  \nEXPLANATION: The study found that the AA and AG genotypes were linked to lower warfarin dose requirements, contributing significantly to the variability in stable warfarin doses among the 250 Thai patients (p < 0.01).",
          "critique": "The generated sentence captures most of the key associations correctly, with only minor differences in specificity. The variant and genotypes mentioned (rs9923231, AA + AG) are different from the ground truth (rs9923231, CT + TT), but the direction of association (decreased warfarin dose) and the phenotypes/conditions (Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, chronic thromboembolic pulmonary hypertension) are largely consistent with the ground truth. The drug mentioned (warfarin) is also correct. The only minor difference is the comparison group, which is GG in the generated sentence instead of CC in the ground truth. Overall, the generated sentence captures the key pharmacogenomic associations very well, with a high degree of similarity to the ground truth."
        },
        {
          "variant": "rs1057910",
          "ground_truth": [
            "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA."
          ],
          "generated": [
            "Genotypes AC + CC of rs1057910 are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to genotype AA.  \nEXPLANATION: The study demonstrated that the presence of the AC and CC genotypes of CYP2C9*3 was linked to lower warfarin dose requirements, contributing to the overall variability in dosing among the 250 Thai patients (p < 0.05)."
          ],
          "score": 0.85,
          "best_similarity": 0.4098360655737705,
          "best_gt": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
          "best_gen": "Genotypes AC + CC of rs1057910 are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to genotype AA.  \nEXPLANATION: The study demonstrated that the presence of the AC and CC genotypes of CYP2C9*3 was linked to lower warfarin dose requirements, contributing to the overall variability in dosing among the 250 Thai patients (p < 0.05).",
          "critique": "The generated sentence captures most of the key associations from the ground truth, with some minor differences in specificity. The variant, genotypes, direction of association (decreased dose), drug (warfarin), and phenotypes (Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, chronic thromboembolic pulmonary hypertension) are all correctly mentioned. The only minor difference is that the ground truth mentions a broader set of phenotypes, while the generated sentence uses more specific terminology (e.g. 'deep vein thrombosis' instead of 'Venous Thrombosis'). Overall, the key pharmacogenomic associations are well captured."
        },
        {
          "variant": "rs2108622",
          "ground_truth": [
            "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC."
          ],
          "generated": [
            "Genotype TT of rs2108622 is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to genotype CC.  \nEXPLANATION: The results indicated that the TT genotype of CYP4F2 rs2108622 accounted for a modest increase in warfarin dose requirements, contributing approximately 1.2% to the variability in doses among the study participants."
          ],
          "score": 0.85,
          "best_similarity": 0.375,
          "best_gt": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
          "best_gen": "Genotype TT of rs2108622 is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to genotype CC.  \nEXPLANATION: The results indicated that the TT genotype of CYP4F2 rs2108622 accounted for a modest increase in warfarin dose requirements, contributing approximately 1.2% to the variability in doses among the study participants.",
          "critique": "The generated sentence captures most of the key associations from the ground truth, with some minor differences in specificity. The variant, genotype, direction of association (increased dose), effect type (dose), and comparison groups are all correctly captured. The phenotypes/conditions are mostly aligned, with some differences in terminology (e.g. 'deep vein thrombosis' instead of 'Venous Thrombosis'). The drug (warfarin) is also correctly mentioned. Overall, the generated sentence provides a good representation of the key pharmacogenomic associations, with only minor deviations from the ground truth."
        },
        {
          "variant": "rs887829",
          "ground_truth": [
            "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T."
          ],
          "generated": [
            "Allele T of rs887829 is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to allele C.  \nEXPLANATION: The study concluded that the UGT1A1 rs887829 polymorphism did not significantly contribute to the variability in warfarin doses, indicating no association with dose requirements in the Thai patient population."
          ],
          "score": 0.8,
          "best_similarity": 0.3333333333333333,
          "best_gt": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
          "best_gen": "Allele T of rs887829 is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, deep vein thrombosis, pulmonary embolism, or chronic thromboembolic pulmonary hypertension as compared to allele C.  \nEXPLANATION: The study concluded that the UGT1A1 rs887829 polymorphism did not significantly contribute to the variability in warfarin doses, indicating no association with dose requirements in the Thai patient population.",
          "critique": "The generated sentence captures most of the key associations from the ground truth, with some minor differences in wording and specificity. The variant, direction of association (not associated), effect type (dose), and comparison groups are all correctly captured. The generated sentence mentions the specific alleles (T vs C) while the ground truth uses the more general 'allele C' and 'allele T'. The generated sentence also lists a more specific set of phenotypes/conditions compared to the ground truth. Overall, the generated sentence accurately captures the key pharmacogenomic associations, with only minor differences in wording and specificity."
        }
      ],
      "generated_extras": []
    }
  ]
}